Patentability Challenges Not Raised in Prior Interference Foreclosed in Subsequent IPR

Apr 1, 2021

Reading Time : 3 min

Patent owner Mexichem Amanco Holdings owns U.S. Patent No. 8,633,340, which covers processes for preparing chlorinated and fluorinated hydrocarbons. In September 2020, The Chemours Company (petitioner) filed a petition for IPR seeking review of certain claims of the ’340 patent.

This was not the first time that petitioner had challenged the ’340 patent at the board. In 2018, the ’340 patent was involved in an interference with one of petitioner’s reissue applications. Pursuant to the board’s instruction, each party in the interference submitted a list of motions they intended to file. Notably, while patent owner sought permission to file motions challenging both priority and patentability of petitioner’s reissue claims, petitioner only included a single motion for judgment on the basis of priority on its motions list. After authorizing the motions, the board noted that petitioner did not include any responsive motion challenging patentability and invited petitioner to seek authorization if it wanted to do so. Ultimately, petitioner never sought authorization to file a responsive motion. After reviewing the parties’ papers, the board held that petitioner’s reissue claims were unpatentable for failing to comply with the written description requirement and entered judgment against petitioner. The board’s decision was affirmed by the Federal Circuit.

Later, in the IPR, patent owner argued that petitioner was estopped from asserting its grounds of unpatentability because petitioner could have, but did not, raise those grounds in the previous interference. Patent owner based its “interference estoppel” argument on 37 C.F.R. § 41.127(a), which provides that a judgment in an interference “disposes of all issues that were, or by motion could have properly been raised and decided.” The board agreed with patent owner and denied institution of the IPR.

In reaching its conclusion, the board first explained that “for more than 35 years” it has been deciding patentability challenges in interferences, including those based on anticipation and obviousness, and further noted there is “complete identity” between the ’340 patent claims challenged in the interference count and the IPR. Thus, it was “beyond dispute” that the patentability of the challenged claims could have been raised in the interference. The board also noted that despite having “repeated opportunity” in the interference to file a patentability motion—including an explicit invitation from the board for a conference call to seek authorization to file a patentability motion—petitioner declined to do so. The board also found that petitioner was “well-acquainted” with the asserted prior art at the time of the interference because that prior art was discussed in the interference and was considered during prosecution of the ’340 patent. Thus, there was no reason for petitioner not to raise the IPR grounds in the interference.

In arguing against estoppel, petitioner maintained that § 41.127(a) should be interpreted such that if a party chooses to challenge patentability, it is incumbent on the party to raise all known patentability arguments. But where, as petitioner did here, a party chooses to only challenge priority, its patentability challenges are not prohibited. The board found petitioner’s interpretation unpersuasive for several reasons. First, it is inconsistent with the text of the regulation because allowing a losing party to raise patentability issues in a subsequent IPR would mean that the prior interference judgment did not dispose of “all issues” that could have been raised in the interference. Second, petitioner’s interpretation improperly conflates the board’s discretion to decide patentability in an interference with a party’s obligation to preserve those issues. On this point, the board explained that “estoppel . . . depends on whether the losing party sought to raise the issue when it had the opportunity to do so and not whether the Board exercised its discretion to reach it.” Finally, the board found that petitioner’s interpretation was contrary to the purpose of § 41.127(a), which is to “encourage the parties to raise issues pertaining to the interfering subject matter, whether they be questions of priority or patentability, so that the Board can assess how best to resolve those questions within the full context of all the issues raised.”

Practice Tip: When deciding what challenges to make in an interference proceeding, a party should be aware of, and take into consideration, the possibility that it may be estopped from later challenging patentability in an IPR. A party involved in an interference should consider raising all patentability challenges of which it is aware, or risk the possibility of being foreclosed from raising them in a subsequent proceeding.

The Chemours Co. FC, LLC v. Mexichem Amanco Holdings SA de CV, IPR2020-01667, Paper 10 (P.T.A.B. March 25, 2021)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.